The SARS-CoV2 surface spike protein is a rational target for COVID-19 vaccination. However, spike protein glycosylation helps the virus evade the immune system, undermining vaccination efforts against newer variants. Dr Chi-Huey Wong’s group at Academia Sinica, Taiwan, is hoping to combat this by glycoengineering protein- and mRNA-based COVID-19 vaccines.

Full content